Life Sciences

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
26 October 2018

Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development

Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies

Read the press release
Microbiotica Attracts Equity Investment  from Seventure’s Health for Life Capital™ Fund
25 October 2018

Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund

The company, which was founded in 2016 to develop transformational technology developed at the Sanger Institute, has made rapid progress in developing a unique capability to...

Read the press release
Enterome signs global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease
23 October 2018

Enterome signs global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease

Enterome, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered...

Read the press release
Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303
4 October 2018

Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human...

Read the press release
LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient
1 October 2018

LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient

LNC Therapeutics, a French biotech company specialized in the gut microbiome-based drug discovery,has announced the launch of a new clinical trial with Stablor®, OBEMINALE 2,...

Read the press release
Safer liver resection: Perioperative assessment of liver function with the LiMAx® test shortens hospital stay and reduces complications after liver surgery
25 July 2018

Safer liver resection: Perioperative assessment of liver function with the LiMAx® test shortens hospital stay and reduces complications after liver surgery

Clinical phase III trial at 6 specialized liver centers demonstrates impressive benefits of the LiMAx® test.

Read the press release